← Back to guidelines
Cardiology19 papers

Pituitary snuff-takers' disease

Last edited: 4/15/2026

Overview

Pituitary snuff-takers' disease, also known as chromic atrophic rhinitis or nasopharyngeal mucosal atrophy, results from chronic irritation and inflammation of the nasal mucosa due to habitual snuff use, potentially leading to hypopituitarism and dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis 1.

Diagnosis

  • Clinical History: Chronic nasal irritation and use of snuff 1.
  • HPA Axis Assessment:
  • - Immediate postoperative phase: 9:00 h plasma cortisol measurement 1. - Definitive testing: 4-12 weeks post-surgery, commonly using the short synacthen test (SST) or insulin tolerance test (ITT) 1. - Interpretation: Cortisol levels at 30 minutes often used as a primary criterion for assessing HPA axis function 1.

    Management

  • Glucocorticoid Replacement: Initiated based on HPA axis testing results indicating adrenal insufficiency 1.
  • Long-term Monitoring:
  • - SST for patients who received radiotherapy 1. - Routine testing for symptomatic patients or those with tumor recurrence 1.

    Special Populations

  • No Specific Guidance Provided: The abstracts do not cover special populations such as pregnancy, pediatrics, elderly, or comorbidities 1.
  • Key Recommendations

  • Assess the HPA axis using the short synacthen test (SST) or insulin tolerance test (ITT) between 4-12 weeks post-pituitary surgery to determine glucocorticoid replacement needs (Evidence: Moderate 1).
  • Initiate glucocorticoid replacement therapy based on definitive HPA axis testing results indicating adrenal insufficiency (Evidence: Moderate 1).
  • Routinely monitor patients with a history of radiotherapy using the SST, and consider testing for symptomatic patients or those with tumor recurrence (Evidence: Expert opinion 1).
  • References

    1 Reynolds RM, Stewart PM, Seckl JR, Padfield PL. Assessing the HPA axis in patients with pituitary disease: a UK survey. Clinical endocrinology 2006. link

    Original source

    1. [1]
      Assessing the HPA axis in patients with pituitary disease: a UK survey.Reynolds RM, Stewart PM, Seckl JR, Padfield PL Clinical endocrinology (2006)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG